Paul Scheuschner
United States
Mr. Jay Flatley serves as Chief Executive Officer and Chairman at Zymergen. While serving as Chief Executive Officer he has served on the Board since January 2020 and has served as Chairperson since April 2021. He served as Board Member at Helix. From December 2013 through July 2016, he served as the Chief Executive Officer of Illumina, Inc. (Illumina), a public company focused on sequencing and array-based solutions for genetic analysis, and from October 1999 through December 2013, he served as the President and Chief Executive Officer of Illumina. Prior to joining Illumina, he co-founded and served as President, Chief Executive Officer, and Director of Molecular Dynamics, a life sciences company focused on genetic discovery and analysis, from 1994 until its sale to Amersham Pharmacia Biotech in 1998. He also served on the board of directors of Illumina from 1999 through May 2021, as the Executive Chair of Illumina from July 2016 through January 2020, and as the Chairman of the Board of Illumina from January 2020 through May 2021. He has also served on the board of directors of Denali Therapeutics Inc., a public biotechnology company, since 2015, and Coherent Inc., a publicly-traded photonics manufacturing company, since 2011; he previously served on the board of directors of Juno Therapeutics, Inc., from 2017 to 2018. He is an advisory board member for U.C. San Diego's Moore Cancer Centre and serves on the board of trustees of the Salk Institute for Biological Studies. He also serves as Advisor at Illumina Ventures.
Individual/Angel